Effects of platelet activating factor antagonist on airway inflammation and airway hyperreactivity in asthma
Li, Q.; Li; Shen, P.; Yu; Wei, Y.
Zhonghua Jiehe He Huxi Zazhi 16(Suppl ): 24-26, 79
In present study, we observed that the effects of PAF antagonist -BN52021 (i.p.) on inflammation in airway wall and the airway hyperreactivity in experimental asthma and the effect of BN52021 inhaled as aerosol on the airway hyperreactivity in stable asthmatics. Results showed: 1. BN52021 (20 mg cntdot kg-1, i.p.) inhibited edema of the bronchial submucosa; accumulation of inflammatory cells in airway wall; formation of mucoemboli in bronchi and increase of airway reactivity. 2. It caused a significant fall of airway reactivity in the stable asthmatics when BN52021 was inhaled as aerosol (2.5 mg, b.i.d.) for 7 days. These observations suggest that PAF play an important role during formation of airway inflammation and of airway hyperreactivity. PAF antagonist might become a new approach to treat asthma.